Nanoparticle, Raman-based Fiber-optic Glucose Sensor

纳米颗粒、基于拉曼的光纤血糖传感器

• 批准号: 6777226
• 负责人: JOSEPH T WALSH
• 金额: $ 13.8万
• 依托单位: NORTHWESTERN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-06-01 至 2005-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6777226
• 关键词: Raman spectrometry; artificial endocrine pancreas; bioengineering /biomedical engineering; biomedical equipment development; biosensor device; clinical biomedical equipment; diabetes mellitus; fiber optics; laboratory rat; male; nanomedicine; nanotechnology

DESCRIPTION (provided by applicant): NIH estimates approximately 17 million Americans have diabetes mellitus, with approximately 1/10 of these being type 1 and the remaining being classified as type 2, gestational, and other. The disease can be characterized by long-term complications involving eyes, kidneys, nerves, and blood vessels are common but are limited with tight glycemic control characterized by near-normal glycosylated hemoglobin. The goal of the proposed research is to prove that a sensor based on Surface Enhanced Raman Spectroscopy (SERS) can be used to measure glucose levels in vivo with sufficient accuracy for feedback control of insulin delivery. We propose to develop the fiber-optic-based sensor, test the sensor in vitro and in vivo, and acquire sufficient data in vivo to specify the system requirements for use in human trials. Much of the previous work in the field of glucose sensing has focused on minimally invasive means of measuring blood glucose levels; such systems will allow patients to avoid repeated painful finger-pricks but glucose control would still be based on patient-dependant feedback control. Implanted electrochemical sensors have been FDA-cleared since mid-1999, but they must be physician implanted and their use in real-time glucose control has been limited. Our preliminary SERS work, based on noble metal nanoparticles has shown the potential accuracy and precision of a SERS sensor for glucose. We propose that an advanced version of this SERS sensor could be passed through the skin into the subcutaneous space, in a manner similar to the placement of insulin-pump-based catheters, and replaced every 3 days, which is the current norm for insulin-pump catheters. The nanoparticle-based SERS system provides a direct measure of glucose concentration, can monitor glucose levels continuously, is not based upon consumables (e.g. enzymes or substrates), and like all Raman-based analysis is specific to glucose and relatively insensitive to confounding analytes. We envision using these sensors to close the feedback loop by using the continuous measurement of glucose to control insulin levels, thus freeing the patient of repeated measurements, carbohydrate-counting, and insulin-dosing problems.

描述（由申请人提供）： NIH估计约有1700万美国人患有糖尿病，其中大约1/10为1型，其余的则被归类为2型，妊娠等。该疾病的特征是涉及眼睛，肾脏，神经和血管的长期并发症很常见，但受到紧密的血糖控制的限制，其特征在于近正常的糖基化血红蛋白。拟议的研究的目的是证明基于表面增强的拉曼光谱法（SER）的传感器可用于在体内测量葡萄糖水平，并具有足够的准确性，以反馈控制胰岛素递送。我们建议开发基于光纤的传感器，在体外和体内测试传感器，并在体内获取足够的数据，以指定在人体试验中使用的系统要求。 以前的葡萄糖感应领域的许多工作都集中在测量血糖水平的最低侵入性手段上。这种系统将允许患者避免反复疼痛的手指刺，但葡萄糖控制仍然基于患者依赖的反馈控制。自1999年中以来，植入的电化学传感器已被FDA清算，但必须是医生植入的，并且在实时葡萄糖控制中的使用受到限制。基于高贵金属纳米颗粒，我们的初步SERS工作表明了SERS传感器对葡萄糖的潜在准确性和精度。我们建议，该SERS传感器的高级版本可以通过与放置基于胰岛素 - 泵基的导管的放置方式将皮肤传递到皮下空间，并每3天更换一次，这是当前的胰岛素 - 泵导管的规范。基于纳米颗粒的SERS系统可直接衡量葡萄糖浓度，可以连续监测葡萄糖水平，而不是基于消耗品（例如酶或底物），并且所有基于拉曼的分析都特定于葡萄糖，并且对混合分析物相对不敏感。我们通过使用连续测量葡萄糖来控制胰岛素水平，从而使使用这些传感器关闭反馈回路，从而使患者重复测量，碳水化合物计数和胰岛素剂量问题。